BioMarin Appoints New Chief Medical Officer and Controller
Ticker: BMRN · Form: 8-K · Filed: Aug 22, 2024 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel-change, management
Related Tickers: BMRN
TL;DR
BioMarin shuffles top medical and finance roles, bringing in Dr. Jeffrey Robert as CMO and Joshua Thompson as Controller.
AI Summary
BioMarin Pharmaceutical Inc. announced on August 16, 2024, changes in its executive team. The company appointed Dr. Jeffrey Robert, MD, PhD, as Chief Medical Officer and Executive Vice President, and Mr. Joshua Thompson as Senior Vice President, Corporate Controller, and Principal Accounting Officer. These appointments are effective immediately.
Why It Matters
Key leadership changes in a pharmaceutical company can impact strategic direction, research and development pipelines, and financial oversight.
Risk Assessment
Risk Level: medium — Changes in key executive positions can introduce uncertainty regarding future strategy and operational execution.
Key Players & Entities
- BioMarin Pharmaceutical Inc. (company) — Registrant
- Dr. Jeffrey Robert, MD, PhD (person) — Appointed Chief Medical Officer and Executive Vice President
- Mr. Joshua Thompson (person) — Appointed Senior Vice President, Corporate Controller, and Principal Accounting Officer
- August 16, 2024 (date) — Effective date of appointments
FAQ
What are the effective dates for the new appointments?
The appointments of Dr. Jeffrey Robert and Mr. Joshua Thompson are effective immediately as of August 16, 2024.
What are the new roles for Dr. Jeffrey Robert and Mr. Joshua Thompson?
Dr. Jeffrey Robert has been appointed Chief Medical Officer and Executive Vice President, and Mr. Joshua Thompson has been appointed Senior Vice President, Corporate Controller, and Principal Accounting Officer.
Has BioMarin Pharmaceutical Inc. undergone any other significant changes reported in this filing?
This filing primarily reports on the appointment of new officers and does not detail other significant changes.
What is the principal executive office address for BioMarin Pharmaceutical Inc.?
The address of the principal executive offices is 770 Lindaro Street, San Rafael, California 94901.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for BioMarin Pharmaceutical Inc. is 68-0397820.
Filing Stats: 447 words · 2 min read · ~1 pages · Grade level 11.7 · Accepted 2024-08-22 17:00:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value BMRN The Nasdaq Global Se
Filing Documents
- d880241d8k.htm (8-K) — 22KB
- 0001193125-24-205405.txt ( ) — 136KB
- bmrn-20240816.xsd (EX-101.SCH) — 3KB
- bmrn-20240816_lab.xml (EX-101.LAB) — 17KB
- bmrn-20240816_pre.xml (EX-101.PRE) — 11KB
- d880241d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOMARIN PHARMACEUTICAL INC., a Delaware corporation Date: August 22, 2024 By: /s/ G. Eric Davis G. Eric Davis Executive Vice President, Chief Legal Officer